PMID

Data

Article Title

Organization

From carbohydrates to drug-like fragments: Rational development of novela-amylase inhibitors.

Freie Universit£T Berlin

Synthesis and biological evaluation of 3,5-disubstituted-4-alkynylisoxozales as a novel class of HSP90 inhibitors.

Chengdu University of Tcm

Structure-activity relationship in a purine-scaffold compound series with selectivity for the endoplasmic reticulum Hsp90 paralog Grp94.

Sloan-Kettering Institute For Cancer Research

Potential C-terminal-domain inhibitors of heat shock protein 90 derived from a C-terminal peptide helix.

Tufts University

Fragment-based hit discovery and structure-based optimization of aminotriazoloquinazolines as novel Hsp90 inhibitors.

Nerviano Medical Sciences

Towards the discovery of drug-like epigallocatechin gallate analogs as Hsp90 inhibitors.

Montclair State University

Differences in conformational dynamics between Plasmodium falciparum and human Hsp90 orthologues enable the structure-based discovery of pathogen-selective inhibitors.

University of Geneva

Identification and optimization of novel Hsp90 inhibitors with tetrahydropyrido[4,3-d]pyrimidines core through shape-based screening.

China Pharmaceutical University

Identification of novel HSP90a/ß isoform selective inhibitors using structure-based drug design. demonstration of potential utility in treating CNS disorders such as Huntington's disease.

Vertex Pharmaceuticals

Discovery of a novel class of highly potent, selective, ATP-competitive, and orally bioavailable inhibitors of the mammalian target of rapamycin (mTOR).

Exelixis

Design, synthesis, and biological evaluation of novel deguelin-based heat shock protein 90 (HSP90) inhibitors targeting proliferation and angiogenesis.

Seoul National University

Modulation of DNA repair by pharmacological inhibitors of the PIKK protein kinase family.

Astrazeneca

Targeting conserved water molecules: design of 4-aryl-5-cyanopyrrolo[2,3-d]pyrimidine Hsp90 inhibitors using fragment-based screening and structure-based optimization.

Vernalis

Fragment-based discovery of hydroxy-indazole-carboxamides as novel small molecule inhibitors of Hsp90.

Merck Serono

Discovery of novel aminoquinazolin-7-yl 6,7-dihydro-indol-4-ones as potent, selective inhibitors of heat shock protein 90.

Serenex

Heat shock protein 90: inhibitors in clinical trials.

Biogen Idec

Potent cytotoxic C-11 modified geldanamycin analogues.

Kosan Biosciences

Discovery and development of heat shock protein 90 inhibitors.

Memorial Sloan-Kettering Cancer Center

Novel 3,4-isoxazolediamides as potent inhibitors of chaperone heat shock protein 90.

Universit£

A small molecule that preferentially binds the closed conformation of Hsp90.

San Diego State University

Tricyclic series of heat shock protein 90 (Hsp90) inhibitors part I: discovery of tricyclic imidazo[4,5-c]pyridines as potent inhibitors of the Hsp90 molecular chaperone.

Sanofi-Aventis Research and Development

Lead identification ofß-lactam and related imine inhibitors of the molecular chaperone heat shock protein 90.

Trinity College

ATPases as drug targets: insights from heat shock proteins 70 and 90.

Vernalis R&D

Integration of ligand and structure-based virtual screening for the identification of the first dual targeting agent for heat shock protein 90 (Hsp90) and tubulin.

Trinity College

Recent developments in fragment-based drug discovery.

Astex Therapeutics

Structure-Activity Relationship Study of Tertiary Alcohol Hsp90?-Selective Inhibitors with Novel Binding Mode.

The University of Notre Dame

Recent advances toward the development of Hsp90 C-terminal inhibitors.

University of Notre Dame

The Emerging Landscape of Small-Molecule Therapeutics for the Treatment of Huntington's Disease.

Aligarh Muslim University

Pan- and isoform-specific inhibition of Hsp90: Design strategy and recent advances.

Shandong University

Identification of potent water soluble purine-scaffold inhibitors of the heat shock protein 90.

Memorial Sloan-Kettering Cancer Center

Thermodynamic Dissection of Potency and Selectivity of Cytosolic Hsp90 Inhibitors.

Taiho Pharmaceutical

Discovering High Potent Hsp90 Inhibitors as Antinasopharyngeal Carcinoma Agents through Fragment Assembling Approach.

Sun Yat-Sen University

The Development of Hsp90?-Selective Inhibitors to Overcome Detriments Associated with

The University of Notre Dame

Synthesis and Structure-Activity Relationships of Inhibitors That Target the C-Terminal MEEVD on Heat Shock Protein 90.

University of New South Wales

Inhibition of Plasmodium falciparum Hsp90 Contributes to the Antimalarial Activities of Aminoalcohol-carbazoles.

Universit£

Heat Shock Protein 90 Inhibitors: An Update on Achievements, Challenges, and Future Directions.

China Pharmaceutical University

Synthesis and evaluation of a novel class Hsp90 inhibitors containing 1-phenylpiperazine scaffold.

China Pharmaceutical University

Heat shock protein 70 inhibitors. 1. 2,5'-thiodipyrimidine and 5-(phenylthio)pyrimidine acrylamides as irreversible binders to an allosteric site on heat shock protein 70.

Memorial Sloan-Kettering Cancer Center

Study of marine natural products including resorcyclic acid lactones from Humicola fuscoatra that reactivate latent HIV-1 expression in an in vitro model of central memory CD4+ T cells.

University of California

Dimeric and trimeric triazole based molecules as a new class of Hsp90 molecular chaperone inhibitors.

University of Salerno

A novel class of small molecule inhibitors of Hsp90.

Yale University

Combining hit identification strategies: fragment-based and in silico approaches to orally active 2-aminothieno[2,3-d]pyrimidine inhibitors of the Hsp90 molecular chaperone.

Vernalis (R&D)

4,5-diarylisoxazole Hsp90 chaperone inhibitors: potential therapeutic agents for the treatment of cancer.

Vernalis (R&D)

Rationally designed high-affinity 2-amino-6-halopurine heat shock protein 90 inhibitors that exhibit potent antitumor activity.

Biogen Idec

7'-substituted benzothiazolothio- and pyridinothiazolothio-purines as potent heat shock protein 90 inhibitors.

Conforma Therapeutics

Orally active purine-based inhibitors of the heat shock protein 90.

Conforma Therapeutics

Structure-based discovery of a new class of Hsp90 inhibitors.

Vernalis (R&D)

3-(5-Chloro-2,4-dihydroxyphenyl)-pyrazole-4-carboxamides as inhibitors of the Hsp90 molecular chaperone.

Vernalis (R&D)

Novel, potent small-molecule inhibitors of the molecular chaperone Hsp90 discovered through structure-based design.

Vernalis (R&D)